[ET Net News Agency, 3 April 2024] HSBC Global Research lowered the target price for
Ali Health (00241) to HKD4.5 from HKD6.5 and maintained the "buy" rating.
The research house said it expects 2HFY24 sales to disappoint given the slowdown in
online drug sales post reopening, active optimization of product mix to retire
unprofitable SKU, and negative drag from y-o-y drop in COVID-19 related products'
transaction. (RC)